PledPharma Evaluates Commercial Potential of Myocardial Infarction Indication

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The results from the MANAMI study, which was presented this morning, show that PLED substance was well tolerated by patients in the study and can be given to patients suffering from serious heart disease without any side-effects. Despite the study’s limited size, a tendency towards clinical effect was seen.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC